Literature DB >> 7954264

Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.

C C Sung1, D K Pearl, S W Coons, B W Scheithauer, P C Johnson, A J Yates.   

Abstract

BACKGROUND: Limitations of classification schemes for brain tumors based solely on morphology have stimulated searches for molecular markers of nosologic and prognostic value. Gangliosides are logical candidates because there are high concentrations of them in the nervous system, there is evidence of their roles in regulation of growth and differentiation, and data from small series suggest correlations between ganglioside composition and glioma type.
METHODS: Ganglioside compositions were determined for 70 primary human brain tumors: 16 low grade astrocytomas (LG), 12 anaplastic astrocytomas (AA), 34 glioblastoma multiformes (GBM), and 8 primitive neuroectodermal tumors (PNET). This method involved identification and quantitation of specific gangliosides using chemical analysis and immunoanalysis.
RESULTS: Among all tumor types, histologic grade correlated with a progressive loss of 1b gangliosides (P < 0.0001). GQ1b was higher in LGs than in AAs (P < 0.001). Both GT1b and GD1b were higher in AAs than GBMs (P < 0.01 and 0.05, respectively) and lower in PNETs than in GBMs (P < 0.05). GM3 was higher in PNETs than in any astrocytoma group and higher in GBMs than in either AAs or LGs. There was a significant difference in the content of 3'-LM1 among all groups (P < 0.005), between AAs and GBMs (P < 0.05), and between low grade ordinary and juvenile pilocytic astrocyomas (P < 0.01). The lacto-series ganglioside 3'-isoLM1 was present in all groups except PNET.
CONCLUSIONS: These results indicate that patterns of gangliosides could be of considerable value in refining the classification and diagnosis of primary human brain tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954264     DOI: 10.1002/1097-0142(19941201)74:11<3010::aid-cncr2820741119>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Glycolipids and myelin proteins in human oligodendrogliomas.

Authors:  C C Sung; R Collins; J Li; D K Pearl; S W Coons; B W Scheithauer; P C Johnson; A J Yates
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

Review 2.  Understanding the stepwise synthesis of glycolipids.

Authors:  Hugo J F Maccioni; Claudio G Giraudo; José Luis Daniotti
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

3.  Gangliosides and neutral glycolipids in ependymal, neuronal and primitive neuroectodermal tumors.

Authors:  A J Yates; T K Franklin; P McKinney; R Collins; T Comas; C P Boesel; D K Pearl
Journal:  J Mol Neurosci       Date:  1999-04       Impact factor: 3.444

4.  Modulation of epidermal growth factor receptor phosphorylation by endogenously expressed gangliosides.

Authors:  A R Zurita; H J Maccioni; J L Daniotti
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

5.  Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression.

Authors:  A M Donson; N K Foreman
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

Review 6.  Ganglioside modulation of the PDGF receptor. A model for ganglioside functions.

Authors:  A J Yates; H E Saqr; J Van Brocklyn
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Expression and localization of Lewis(x) glycolipids and GD1a ganglioside in human glioma cells.

Authors:  T Ariga; S Bhat; T Kanda; M Yamawaki; T Tai; Y Kushi; T Kasama; S Handa; R K Yu
Journal:  Glycoconj J       Date:  1996-04       Impact factor: 2.916

8.  A method for visualization of "omic" datasets for sphingolipid metabolism to predict potentially interesting differences.

Authors:  Amin A Momin; Hyejung Park; Brent J Portz; Christopher A Haynes; Rebecca L Shaner; Samuel L Kelly; I King Jordan; Alfred H Merrill
Journal:  J Lipid Res       Date:  2011-03-17       Impact factor: 5.922

Review 9.  Re-configuration of sphingolipid metabolism by oncogenic transformation.

Authors:  Anthony S Don; Xin Y Lim; Timothy A Couttas
Journal:  Biomolecules       Date:  2014-03-14

10.  An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.

Authors:  Shoko Yoshida; Haruhiko Kawaguchi; Shigeki Sato; Ryuzo Ueda; Koichi Furukawa
Journal:  Jpn J Cancer Res       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.